
Opinion|Videos|April 11, 2025
Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
Listen
0:00 / 0:00
Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.
Advertisement
Timecodes:
1:25- Rationale for high dose aflibercept
5:00- PULSAR trial for AMD
12:00- PHOTON trial for DME
16:21- Changing practice patterns
22:29- Faricimab and role of ang-2 inhibition
28:30 Impact of new therapies
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
European Society of Cardiology 2026 Preview: 6 Trials to Know
2
Rethinking CKD: AKI's Long-Term Impact and the Push for Earlier Intervention
3
MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD
4
Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026
5







































































